Synairgen Seeks FDA, EMA Engagement on Covid-19 Drug

Jul.21 — Synairgen Plc Chief Executive Officer Richard Marsden discusses the company’s experimental drug which in a clinical trial cut the risk of developing the worst symptoms of Covid-19. Synairgen, a tiny pharmaceutical firm born out of a U.K. university, will now enter discussions with the U.S. Food and Drug Administration and the European Medicines Agency, Marsden said in an interview on “Bloomberg Surveillance.”